Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 a) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis

Data de publicação:

Autores da FMUP

  • Fernando José Magro Dias

    Autor

Participantes de fora da FMUP

  • Poenariu, Ioan Sabin
  • Boldeanu, Lidia
  • Ungureanu, Bogdan Silviu
  • Caragea, Daniel Cosmin
  • Cristea, Oana Mariana
  • Padureanu, Vlad
  • Silosi, Isabela
  • Ungureanu, Anca Marinela
  • Statie, Razvan-Cristian
  • Ciobanu, Alina Elena
  • Gheonea, Dan Ionut
  • Osiac, Eugen
  • Boldeanu, Mihail Virgil
  • Estevinho, Maria Manuela

Unidades de investigação

Abstract

We intended to investigate the presence and medical application of serum hypoxia-inducible factor-1 alpha (HIF-1 alpha) along with the already known systemic inflammatory markers and the new one's inflammatory indices, the proportion of mean corpuscular volume and lymphocytes (MCVL) and the cumulative inflammatory index (IIC), for patients with ulcerative colitis (UC). We sought to establish correlations that may be present between the serum levels of HIF-1 alpha and these inflammatory indices, as well as their relationship with disease activity and the extent of UC, which can provide us with a more precise understanding of the evolution, prognosis, and future well-being of patients. Serum samples were collected from 46 patients diagnosed with UC and 23 controls. For our assessment of the serum levels of HIF-1 alpha, we used the Enzyme-Linked Immunosorbent Assay (ELISA) technique. Thus, for HIF-1 alpha we detected significantly higher values in more severe and more extensive UC. When it came to MCVL and IIC, we observed statistically significant differences between the three groups being compared (Severe, Moderate, and Mild). Our study highlighted that HIF-1 alpha correlated much better with a disease activity score, MCVL, and IIC. With MCVL and IIC, a strong and very strong correlation had formed between them and well-known inflammation indices. By examining the ROC curves of the analyzed parameters, we recognized that TWI (accuracy of 83.70%) provides the best discrimination of patients with early forms of UC, followed by HIF-1 alpha (73.90% accuracy), MCVL (70.90% accuracy), and PLR (70.40%). In our study, we observed that HIF-1 alpha, MCVL, and PLR had the same sensitivity (73.33%) but HIF-1 alpha had a much better specificity (60.87% vs. 58.70%, and 54.35%). Also, in addition to the PLR, HIF-1 alpha and MCVL can be used as independent predictor factors in the discrimination of patients with early forms of UC.

Dados da publicação

ISSN/ISSNe:
2227-9059, 2227-9059

Biomedicines  MDPI AG

Tipo:
Article
Páginas:
-
PubMed:
38137357

Citações Recebidas na Web of Science: 7

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • ulcerative colitis; hypoxia-inducible factor-1 alpha; IIC; cumulative inflammatory index; MCVL; average crepuscular volume-lymphocyte ratio; hematologic markers

Projetos associados

Gut microbiome and IBD therapy: an interplay?

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (GutIBD) . 2021

Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (IronIBD) . 2021

Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (4WARD) . 2021

Isolated Ulceration of Crohn’s Anastomosis

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2021

Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2022

Burden of Inflammatory Bowel Disease in Portugal

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico (Inflammatory Bowel) . 2023

Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2021

Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2019

Citar a publicação

Partilhar a publicação